secwatch.observer — SEC 8-K summary
======================================

Issuer:     Baudax Bio, Inc. (—)
CIK:        0001780097
Form:       8-K
Filed at:   2023-06-15T23:59:59+00:00
Accession:  0001193125-23-167910
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Baudax Bio receives Nasdaq bid price deficiency; ineligible for cure period due to prior reverse splits
--------------------------------------------------------------------------------

- New deficiency: closing bid price below $1.00 for 30 consecutive business days (Rule 5550(a)(2)).
- Company ineligible for compliance period due to two reverse stock splits with cumulative ratio >=250:1.
- This is an additional basis for delisting; Panel will consider along with existing equity deficiency.
- Stock continues trading on Nasdaq under BXRX pending hearing; company will present a compliance plan.
- No assurance that the Panel will accept the plan or that the company can regain compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1780097/000119312523167910/0001193125-23-167910-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1780097/000119312523167910/d461441d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-167910

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer